Table 1 Trastuzumab-mediated cardiotoxicity rates in patients across various studies

Seidman et al. [23]

Cardiovascular decline, defined as decreased LVEF or symptoms of congestive heart failure (CHF), present in 7% of patients when trastuzumab was used as a single agent

Calvillo-Arguelles et al. [21]

3-year cumulative incidence of cardiotoxicity was 35% (defined as a ≥ 10% decline in LVEF, to < 55% without symptoms OR ≥ 5% decrease in LVEF, to < 55% with symptoms, in at least 1 MUGA scan) for women diagnosed with HER2 positive breast cancer, and who had received > 12 months of trastuzumab therapy

Chen et al. [7]

Meta-analysis of 10 randomised controlled trials (RCT) where incidence of CHF and LVEF decrease were 1.9% and 7.5% respectively in HER2 positive breast cancer patients receiving trastuzumab

Thavendiranathan et al. [24]

Cumulative incidence of hospitalisation/emergency room visits for CHF, outpatient diagnosis of CHF or cardiovascular death was 5.1% for trastuzumab treatment without anthracyclines